Nexvet Biopharma Announces Closing of Initial Public Offering

DUBLIN, Ireland and MELBOURNE, Australia, Feb. 11, 2015 (GLOBE NEWSWIRE) -- Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq: NVET) today announced the closing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $10.00 per share, resulting in aggregate gross proceeds of $40 million, before underwriting discounts, commissions and estimated offering expenses. Nexvet's common stock is listed on The NASDAQ Global Market under the ticker symbol "NVET."

BofA Merrill Lynch and Cowen and Company, LLC acted as joint book-running managers for the offering. Piper Jaffray and JMP Securities acted as co-managers for the offering.

A registration statement relating to the common stock offered and sold by Nexvet was declared effective by the U.S. Securities and Exchange Commission February 5, 2015. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Copies of the final prospectus related to the offering may be obtained, when available, from BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attention: Prospectus Department, e-mail: [email protected], or from Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling 631-274-2806, or by faxing 631-254-7140.

About Nexvet (www.nexvet.com)

Nexvet is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet's proprietary PETization™ platform is designed to rapidly create monoclonal antibodies ("mAbs") that are recognized as "self" or "native" by an animal's immune system, a property Nexvet refers to as "100% species-specificity." Nexvet's product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.

CONTACT: Investors
         Candice Knoll
         Blueprint Life Science Group
         +1 415-375-3340 Ext. 105
         [email protected]

         Media
         Lynn Granito
         Berry & Company Public Relations
         +1 212-253-8881
         [email protected]

You May Also Be Interested In

• SEC accuses ex-BofA senior banker Satsky of insider trading - Bloomberg
• Andersen closes secondary offering of 4.9M shares at $44 each
• Elroy Air wins $46M U.S. Army contract for cargo drone system